Jan 05, 2021
Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial
Aug 10, 2020
Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Jun 30, 2020
Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates
Jun 23, 2020
Marker Therapeutics Receives USAN Approval for "zelenoleucel" as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia
May 29, 2020
Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
May 04, 2020
Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020
Apr 29, 2020
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia
Mar 12, 2020
Marker Therapeutics Reports Full Year 2019 Operating and Financial Results
Mar 02, 2020
Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million
Feb 11, 2020
Marker Therapeutics Announces Update to its Clinical Program in AML
Nov 25, 2019
Marker Therapeutics to Present at Two Upcoming Investor Conferences
Nov 12, 2019
Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results
Nov 11, 2019
Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019
Aug 15, 2019
Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs
Aug 08, 2019
Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results
Aug 06, 2019
Marker Therapeutics Appoints Steve Elms to its Board of Directors
Jul 20, 2019
Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR
Jul 17, 2019
Marker Therapeutics to Host Conference Call and Webcast to Review Interim Results from Phase 1/2 Clinical Trial with its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma
Jun 20, 2019
Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma
May 21, 2019
Marker Therapeutics to Present at Two Upcoming Investor Conferences